On December 1, 2025, the World Health Organization published its first guideline addressing GLP-1-based therapies — GLP-1 receptor agonists and GLP-1/GIP dual agonists — for adults living with obesity. This article explains what the guideline document says and how WHO arrived at it. It is not medical advice, a treatment recommendation, or guidance on dosage; decisions about individual treatment belong with a person and their own doctor, informed by their specific health history.
The short version: WHO's guideline conditionally supports GLP-1 therapies as a long-term treatment (defined as continuous therapy for at least 6 months) for adults with obesity, based on moderate-certainty evidence. It frames obesity as a chronic, complex disease requiring lifelong care, and positions GLP-1 medication as one part of a comprehensive strategy that also includes behavioral support and long-term follow-up — not a standalone treatment. A guideline development group is set to reconvene in early 2026 to build risk-stratification tools and review emerging evidence.
What "conditional" and "moderate-certainty" mean here
WHO guidelines use a formal grading system for how strongly they back a recommendation and how much they trust the evidence behind it. A conditional recommendation — as opposed to a strong one — signals that the guideline development group judged the treatment appropriate for many, but not necessarily all, patients, and that individual circumstances and preferences should weigh heavily in the decision. Moderate-certainty evidence means there's reasonable confidence in the effect estimate, but further research could still change it. Together, these qualifiers mean the guideline is a considered recommendation, not a blanket mandate.
The guideline treats obesity as chronic, not episodic
A central framing choice in the document is describing obesity as "a chronic, complex disease that requires lifelong care" — a framing that shapes the rest of the guideline's recommendations. Under that framing, GLP-1 therapy is positioned within a comprehensive, ongoing treatment strategy: medication combined with behavioral support focused on diet and physical activity, plus long-term follow-up, rather than a short course intended to produce a one-time result.
Behavioral therapy isn't optional in the guideline's framing
The guideline specifically calls for "intensive behavioral therapy" to be combined with GLP-1 medications for obesity treatment — the document does not present medication as a replacement for behavioral and lifestyle support, but as a complement to it within a combined care plan.
What's still being worked out
WHO's guideline development group is scheduled to reconvene in early 2026 to develop risk-stratification tools (helping identify which patients are better or worse candidates), support member states with cost-effectiveness analysis for their own health systems, and review emerging evidence on discontinuation, titration, maintenance strategies, and how these therapies fit into broader treatment algorithms. That ongoing work signals the December 2025 guideline is a first formal step, not WHO's final word on the subject.
What this guideline is — and isn't
- It is: a formal international health-policy document meant to guide national health systems and clinicians on evidence-based use of a treatment class.
- It is not: personalized medical advice, a prescription recommendation, or dosage guidance for any individual.
- It does not: suggest GLP-1 therapy replaces diet, exercise, or clinical judgment about a specific patient's circumstances.
Anyone considering GLP-1 therapy for themselves should discuss it with their own doctor, who can weigh their specific health history — something a global policy guideline, by design, cannot do.